DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Letermoviris the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in two NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Letermovir has seventy-nine patent family members in forty-four countries.
One supplier is listed for this compound.
Recent Clinical Trials for letermovir
Identify potential brand extensions & 505(b)(2) entrants
|Ohio State University Comprehensive Cancer Center||Phase 2|
|National Cancer Institute (NCI)||Phase 2|
|City of Hope Medical Center||Phase 2|
Pharmacology for letermovir
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Merck Sharp Dohme||PREVYMIS||letermovir||TABLET;ORAL||209939-001||Nov 8, 2017||RX||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|Merck Sharp Dohme||PREVYMIS||letermovir||SOLUTION;INTRAVENOUS||209940-002||Nov 8, 2017||RX||Yes||Yes||Start Trial||Start Trial||Y||Y||Y||Start Trial|
|Merck Sharp Dohme||PREVYMIS||letermovir||TABLET;ORAL||209939-002||Nov 8, 2017||RX||Yes||Yes||Start Trial||Start Trial||Y||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1622880||C 2018 027||Romania||Start Trial||PRODUCT NAME: LETERMOVIR SAU SAREA SA, SOLVATUL SAU, SAU SOLVATUL SARII SALE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1245; DATE OF NATIONAL AUTHORISATION: 20180108; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1245; DATE OF FIRST AUTHORISATION IN EEA: 20180108|
|1622880||C201830035||Spain||Start Trial||PRODUCT NAME: LETERMOVIR, SUS SALES Y SOLVATOS, Y SOLVATOS DE LAS SALES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1245; DATE OF AUTHORISATION: 20180108; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1245; DATE OF FIRST AUTHORISATION IN EEA: 20180108|
|1622880||18C1029||France||Start Trial||PRODUCT NAME: LETERMOVIR AINSI QUE SES SELS,SOLVATES ET SELS SOLVATES,PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/17/1245/001-004 20180110|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.